0 301

Cited 4 times in

ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models

DC Field Value Language
dc.contributor.author김혜련-
dc.contributor.author박혜지-
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.contributor.author한주연-
dc.date.accessioned2017-10-26T07:29:37Z-
dc.date.available2017-10-26T07:29:37Z-
dc.date.issued2016-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152103-
dc.description.abstractOBJECTIVES: The epidermal growth factor receptor (EGFR) abnormalities including amplification, mutation, and overexpression are frequent in non-small cell lung cancer (NSCLC). We investigated in vitro and in vivo antitumor activity of ER2, a novel human anti-EGFR monoclonal antibody, in NSCLC. METHODS: A panel of NSCLC cell lines (A549, H460, H322, H358, H1299, HCC827, PC9, H1975, and PC9-GR) was used to evaluate in vitro antitumor activity of ER2 and cetuximab. The inhibitory effects of ER2 and cetuximab on downstream signaling were assessed by western blot. Secreted VEGF was measured by Human VEGF Quantikine ELISA kit. Antitumor effects of ER2 and cetuximab as single agents and in combination with cisplatin were evaluated in H322, HCC827 and A549 xenograft models. RESULTS: ER2 efficiently inhibits EGFR and its downstream signaling molecules including Akt and Erk1/2 in NSCLC cell lines with wild-type or mutant EGFR. ER2 inhibited cell viability of H322, HCC827 and A549 cells in a dose-dependent manner by inducing cell cycle arrest and apoptosis. Also, ER2 suppressed EGF-stimulated VEGF production as efficiently as cetuximab in H322, HCC827 and A549 cells. Moreover, ER2 alone and in combination with cisplatin showed a significant anti-tumor efficacy in xenograft mouse models. CONCLUSION: Taken together, ER2 has significant anti-tumor activity in in vitro and in vivo NSCLC models, suggesting a rationale for clinical development of ER2 in NSCLC.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Scientific Publishers-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHAntibodies, Monoclonal, Humanized/pharmacology*-
dc.subject.MESHAntineoplastic Agents/pharmacology*-
dc.subject.MESHApoptosis/drug effects-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/metabolism*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology*-
dc.subject.MESHCell Cycle Checkpoints/drug effects-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCisplatin/pharmacology-
dc.subject.MESHDisease Models, Animal-
dc.subject.MESHDrug Synergism-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy-
dc.subject.MESHLung Neoplasms/metabolism*-
dc.subject.MESHLung Neoplasms/pathology*-
dc.subject.MESHMice-
dc.subject.MESHReceptor, Epidermal Growth Factor/antagonists & inhibitors*-
dc.subject.MESHReceptor, Epidermal Growth Factor/metabolism-
dc.subject.MESHSignal Transduction/drug effects-
dc.subject.MESHXenograft Model Antitumor Assays-
dc.titleER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models-
dc.typeArticle-
dc.publisher.locationIreland-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHan Na Kang-
dc.contributor.googleauthorSe-Ho Kim-
dc.contributor.googleauthorMi Ran Yun-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorMin-Soo Kim-
dc.contributor.googleauthorKwang-Won Hong-
dc.contributor.googleauthorSung-Moo Kim-
dc.contributor.googleauthorHwan Kim-
dc.contributor.googleauthorKyoung-Ho Pyo-
dc.contributor.googleauthorHye Ji Park-
dc.contributor.googleauthorJoo Yeun Han-
dc.contributor.googleauthorHyun A Youn-
dc.contributor.googleauthorKi-Hwan Chang-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1016/j.lungcan.2016.02.013-
dc.contributor.localIdA04945-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.contributor.localIdA04809-
dc.contributor.localIdA05066-
dc.contributor.localIdA01166-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid27040853-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500216302343?via%3Dihub-
dc.subject.keywordCetuximab-
dc.subject.keywordER2-
dc.subject.keywordEpidermal growth factor receptor-
dc.subject.keywordMonoclonal antibody-
dc.subject.keywordNon-small cell lung cancer-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNamePark, Hye Ji-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNamePyo, Kyoung Ho-
dc.contributor.alternativeNameHan, Joo Yeun-
dc.contributor.affiliatedAuthorPark, Hye Ji-
dc.contributor.affiliatedAuthorLim, Sun Min-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorHan, Joo Yeun-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.citation.volume95-
dc.citation.startPage57-
dc.citation.endPage64-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.95 : 57-64, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid46883-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.